SUBSCRIBE
SUBSCRIBE

Synexa Life Sciences

Synexa Life Sciences is a biomarker and bioanalytical lab CRO, specialising in the development, validation and delivery of a wide range of complex and custom-designed assays.

With a team of over 200 staff across three global laboratory locations; Manchester, Turku (Finland) and Cape Town, we provide innovative solutions to support our customers to achieve their clinical milestones.

Our main areas of expertise include biomarker identification and development, large and small molecule clinical bioanalysis, (soluble) biomarker analysis (utilising MSD, LC-MS/MS, ELISA, RIA, fluorescence and luminescence-based technologies), cell biology (including flow cytometry, ELISpot and Fluorospot) and genomic services to support clinical trials and translational studies.

We pride ourselves on our deep scientific expertise and ability to tackle complex problems, translating them into robust and reliable assays to support clinical trial sample analysis.

NEWS
Handshake gesture contemporary collage art. Celebrating success, congratulating for financial and business partnership, job contract deal, mutual friendship and respect. Abstract illustration isolated.
Collaboration
Boehringer Ingelheim Boosts I&I Portfolio With $357M in Biobucks for Cue
At the heart of the licensing deal is CUE-501, a bispecific molecule that can selectively deplete B cells to address autoimmune and inflammatory conditions.
April 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Symbol of money dollar from colored pills and capsules on green background. Expensive medicine and medical insurance
Tariffs
Trump Opens National Security Probe on Pharma Imports, Signaling Imminent Tariffs
Trump could use the findings of the probe to impose certain trade restrictions on pharma products, including tariffs.
April 15, 2025
 · 
2 min read
 · 
Tristan Manalac
Scientists working with DNA. Doctors doing laboratory research. Medicine and technology. Genetic testing DNA testing genetic diagnosis concept. Vector, illustration, esp.
Gene editing
Verve’s Base Editor ‘Numerically Beats’ Other Cholesterol-Lowering Drugs
In a Phase Ib trial, VERVE-102 showed it could lower bad cholesterol across doses, setting up an opt-in decision for Eli Lilly and a showdown with Novartis.
April 14, 2025
 · 
2 min read
 · 
Dan Samorodnitsky
Businessman pulling rope trying to lift up falling graph.
Weight Loss
Viking Rises as Pfizer’s Oral Obesity Med Falters
Viking Therapeutics enjoyed a nice share rally on the news that rival Pfizer is discontinuing obesity candidate danuglipron. But the biotech has a long way to go to recover after six straight months of decline.
April 14, 2025
 · 
3 min read
 · 
Annalee Armstrong
Reducing the dose of medicine. Splitting the pills. Health care and medication. White medical pill broken into three pieces on blue background.
Weight loss
Pfizer Drops Lead Obesity Asset After Liver Safety Concerns, Overall Review
Pfizer’s discontinuation of danuglipron brings the company down to a single molecule in its obesity pipeline.
April 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Flat lay composition with sleep eye mask, dream book and alarm clock on dark blue background. Healthy sleeping concept.
Legal
Vanda Sues FDA Again, This Time Over Off-Label Use of Hetlioz for Jet Lag
Vanda is criticizing the FDA’s restrictions on information companies can provide regarding off-label use of approved medicines.
April 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Elevated View Of Pink Piggybank And Blue Arrow Signs Showing Various Direction
Mergers & acquisitions
Theratechnologies in Talks with Anonymous Potential Buyer While Fielding Future Pak Buyout Offer
Future Pak—whose acquisition offer was rejected by Vanda Pharmaceuticals last summer—is offering to buy Theratechnologies for an unsolicited $255 million. The Canadian biotech is under an exclusivity agreement with another yet-to-be-disclosed potential purchaser.
April 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Robert F. Kennedy Jr. is sworn in as Secretary of the Department of Health and Human Services at the White House, Thursday, February 13, 2025. (Official White House Photo by Joyce Boghosian.)
Government
HHS Secretary Kennedy Accuses FDA Employees of Being Industry ‘Sock Puppet’
Leerink analysts warned that Kennedy’s remarks to FDA staff would likely be a negative for the biotech industry.
April 14, 2025
 · 
2 min read
 · 
Tristan Manalac
Genetically engineered chimeric antigen receptor immune cell with implanted mrna gene strand - 3d illustration
In partnership with GenScript
Beyond the Breakthrough: Industry Leaders Address Key Hurdles Facing Cell and Gene Therapies
At the GenScript Biotech Global Forum 2025, industry leaders celebrated CAR T cell therapy achievements while discussing ongoing challenges in manufacturing, distribution, treatment center capacity, and global payment structures for cell and gene therapies.
April 14, 2025
 · 
6 min read
 · 
BioSpace Insights
Load More
Visit website
Email Us
IN THE PRESS
Press Releases
Waters Sets a New Benchmark for Robustness and Sensitivity for High-Throughput Labs with the Xevo TQ Absolute XR Mass Spectrometer
June 2, 2025
 · 
4 min read
BioMidwest
Inotiv, Inc. Announces New Site Openings and Expansions Supporting Additional Capacity and Service Offerings
December 8, 2022
 · 
4 min read
Business
Parexel Announces Strategic Collaboration with Synexa Life Sciences and Drawbridge Health for COVID-19 Clinical Serology Testing Solution
November 2, 2020
 · 
4 min read
JOBS